Evaluation of the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-risk Neuroblastoma

High-risk Neuroblastoma Clinical Trial

Official title:
An Open-Label, Multi-Center, Single-Arm, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-Risk Neuroblastoma

Status Completed

Clinical Trial Summary

This is an open-label, multi-center, single-arm, Phase 1 study. The purpose of this study is for evaluating the safety and pharmacokinetics of dinutuximab beta as maintenance therapy in Chinese patients with high-risk neuroblastoma

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05373901
Study type	Interventional
Source	BeiGene
Contact
Status	Completed
Phase	Phase 1
Start date	June 7, 2022
Completion date	June 28, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06057948` - A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma	Phase 2
Not yet recruiting	`NCT06335745` - PediCARE Health Equity Intervention in High-Risk Neuroblastoma	N/A
Recruiting	`NCT05489887` - Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma	Phase 2
Recruiting	`NCT04221035` - High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)	Phase 3
Recruiting	`NCT05650749` - GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma	Phase 1
Not yet recruiting	`NCT06182410` - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma	Phase 2
Recruiting	`NCT05272371` - Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease	Phase 1
No longer available	`NCT04501757` - Naxitamab and GM-CSF in People With Neuroblastoma